Nycomed names new chairman
Nycomed Amersham this month named a new chairman, sparking speculation that the company’s Norwegian influence is decreasing. Richard Lapthorne, Nycomed’s deputy chairman, will trade jobs with chairman Johan Odfjell at the conclusion of the
Nycomed Amersham this month named a new chairman, sparking speculation that the companys Norwegian influence is decreasing. Richard Lapthorne, Nycomeds deputy chairman, will trade jobs with chairman Johan Odfjell at the conclusion of the firms annual general meeting on May 6. Odfjell was appointed chairman when Nycomed and Amersham merged into a $2.5 billion drug company in October 1997 (SCAN 7/9/97 and 10/29/97). The Buckinghamshire, U.K., and Oslo, Norway, company also announced that its executive director, Tore Laerdal, will retire after the meeting.
At the time of the merger, the two companies took care to balance the new entitys executive lineup between U.K. and Norwegian officers. But industry experts wonder if the company is gradually leaning toward Buckinghamshire. Lapthorne and Odfjells switch is the latest in a series of personnel shifts in which many Norway-based executives have left the company.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
